



December 30, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

JCR Signs Provisional Production Master Service Agreement with AstraZeneca Regarding Domestic Production of COVID-19 Vaccine Bulk Product

December 30, 2020 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that it has signed a provisional production master service agreement with AstraZeneca K.K. (Headquarters: Kita-ku, Osaka, "AstraZeneca") regarding the production of bulk product in Japan for the adenovirus vector-based COVID-19 vaccine, known as AZD1222 ("the vaccine"). The vaccine is currently being developed by AstraZeneca.

JCR has signed an agreement with AstraZeneca on (1) undertaking the domestic production of bulk product of the vaccine that AstraZeneca will introduce in Japan and (2) securing a production line at the Murotani Plant for the production of it.

As a pharmaceutical company with manufacturing capabilities for biopharmaceuticals, JCR will accelerate manufacturing of bulk product for the vaccine with the support of its research members engaged in the development of JCR's gene therapy technology. JCR will make every effort to ensure stable supply of this vaccine in Japan in order to contribute to a potential solution to the coronavirus pandemic at the earliest possible opportunity and to help enhance people's health and wellness.

JCR is currently assessing the impact of this event on its consolidated financial results for the fiscal year ending on March 31, 2021. JCR will announce any need for potential adjustments by timely disclosure.

[About JCR Pharmaceuticals]

JCR is a specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products," drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at

this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

END

###